SCF ENCYCLOPEDIA ENTRY

TUBERCULOSIS (TB)

I. SCOPE & POSITIONING

Pathogen / Etiology: Mycobacterium tuberculosis

Classification: Bacterial (acid-fast, slow-growing, intracellular pathogen)

Transmission:

• Airborne (inhalation of respiratory droplets)

Primary Tropism:

• Lungs (primary)
• Secondary: lymph nodes, CNS, bones, kidneys

SCF Classification:

Chronic Intracellular Granulomatous Immune-Evasive Pulmonary–Systemic Necrotizing Persistence Disorder (CIGIP-SNPD Class)

II. GLOBAL & CLINICAL SIGNIFICANCE

• One of the leading infectious causes of death worldwide
• Can remain latent for years
• Reactivates under immune compromise

Clinical Hallmarks:

Active TB:

• Chronic cough
• Hemoptysis (coughing blood)
• Fever
• Night sweats
• Weight loss

Critical Risks:

• Lung destruction (cavitation)
• Disseminated TB (miliary TB)
• TB meningitis

Aligned SCF Clinical Domains:

• C6: Pulmonary Systems
• C3: Neuroimmune Systems
• C2: Infectious & Inflammatory Medicine
• C12: Chronic Infectious Diseases

III. ETIOPATHOGENIC CORE

Primary Mechanisms:

• Inhalation → alveolar macrophage infection
• Intracellular survival within macrophages
• Formation of granulomas
• Latency and potential reactivation

Key Drivers:

• Immune evasion (phagosome–lysosome inhibition)
• Chronic inflammation
• Tissue necrosis

IV. SCF FAULT ARCHITECTURE

Key Insight:

Tuberculosis is a host–pathogen equilibrium disorder, where:

• The immune system contains the infection
• But also contributes to tissue damage

V. MULTI-OMICS PATHOGENESIS MAP (Granulomatous Persistence Model)

A. Genomics

• Complex genome enabling:
• Dormancy
• Stress adaptation

B. Transcriptomics

• Dormancy genes activated under hypoxia
• Immune evasion pathways expressed

C. Proteomics

• Cell wall lipids:
• Mycolic acids → resistance to immune attack
• ESAT-6:
• Disrupts host membranes

D. Epigenomics

• Chronic immune activation
• Immune tolerance/exhaustion in latency

E. Metabolomics

• Hypoxic granuloma metabolism
• Shift to lipid-based energy use

F. Interactomics

• Bacteria–macrophage interaction
• Immune cell recruitment → granuloma

G. Pulmonary Interface

• Alveolar infection
• Granuloma formation
• Caseous necrosis (cheese-like tissue death)

VI. PATHOGENESIS FLOW (SCF LOGIC)

Inhalation → Macrophage infection → Intracellular survival → Granuloma formation → Latency → Reactivation → Tissue destruction

VII. CLINICAL SPECTRUM

1. LATENT TB

Features:

• Asymptomatic
• Contained infection

2. ACTIVE TB

Features:

• Pulmonary symptoms
• Systemic illness

3. EXTRAPULMONARY TB

Sites:

• CNS (TB meningitis)
• Bone (Pott’s disease)
• Lymph nodes

4. MILIARY TB

Features:

• Disseminated infection
• Multi-organ involvement

VIII. SCF DISEASE-ORIGIN MODEL

A. Core Mechanisms:

• Intracellular persistence
• Granuloma formation
• Immune-mediated damage

B. SCF Classification:

• Primary: Chronic Intracellular Infection
• Secondary: Granulomatous Inflammatory Disorder

IX. SCF TRINITY FRAMEWORK MAPPING

Interpretation:

TB represents a containment failure model, where:

• The immune system walls off infection
• But cannot fully eliminate it

X. SCF PCR THERAPEUTIC STRATEGY

1. PREVENTATIVE (P)

• BCG vaccination (limited efficacy)
• Infection control (airborne precautions)
• Screening (high-risk populations)

2. CURATIVE (C)

Standard Therapy (Multi-Drug Regimen):

• Isoniazid
• Rifampin
• Pyrazinamide
• Ethambutol

Duration:

• 6 months or longer

Key SCF Insight:

Combination therapy prevents resistance and targets different bacterial states

3. RESTORATIVE (R)

• Lung function recovery
• Nutritional support
• Immune system strengthening

XI. CURRENT STANDARD OF CARE

• Long-term antibiotic therapy
• Directly observed therapy (DOT)
• Monitoring for drug resistance

XII. SCF THERAPEUTIC ENGINEERING OPPORTUNITIES

High-Value Targets:

• Intracellular survival pathways
• Dormancy mechanisms
• Granuloma microenvironment

SCF Design Strategy:

• Host-directed therapies
• Anti-dormancy agents
• Granuloma-penetrating drugs

XIII. RHENOVA INTEGRATION (REDOX–HYPOXIA LOGIC)

Core Disruption:

• Hypoxic granuloma environment
• Oxidative stress
• Impaired oxygen exchange

SCF–RHENOVA Role:

• Map hypoxia zones
• Optimize drug delivery
• Predict reactivation risk

XIV. TRANSLATIONAL BLUEPRINT (FDA-ALIGNED)

Preclinical:

• Macrophage infection models
• Dormancy models

Clinical:

• Early detection
• Long-term treatment adherence
• Drug-resistant TB management

Biomarkers:

• Sputum smear and culture
• PCR (GeneXpert)
• Interferon-gamma release assays (IGRA)

XV. SCF DBI INTERPRETATION

Insight:

Tuberculosis represents a DBI equilibrium persistence model, where the pathogen survives within immune containment zones.

XVI. SCF LAYMAN’S TRANSLATION SUMMARY

Tuberculosis is a bacterial infection that mainly affects the lungs.

It:

• Spreads through the air
• Can stay inactive in the body for years
• Causes serious illness if it becomes active

SCF treatment focuses on:

• Long-term antibiotics
• Preventing spread
• Supporting recovery

XVII. MASTER REGISTRY INDEX

• SCF-BACT-TB-0001 — Tuberculosis Entry
• SCF-INTRACELLULAR-0002 — Persistence Module
• SCF-PULMONARY-0003 — Lung Registry
• SCF-RHENOVA-HYPOXIA-0004 — Oxygen Mapping
• SCF-DBI-GRANULOMA-0005 — Containment Model

NEXT STEP OPTIONS

If you want to go deeper, I can generate:

• SCF comparison: TB vs Leprosy vs NTM infections
• API discovery targeting TB dormancy and granuloma penetration
• Drug-resistant TB SCF therapeutic strategy
• Host-directed therapy platform for TB (SCF)